---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-342495"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2026-08-10T20:30:43+00:00"
generated_at: "2026-08-10T20:33:54.281166+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics reports 2Q26 net loss $26.8M; advances VMT-α-NET toward Phase 3

## Summary
- Net loss $26.8M ($0.22/share) vs $21.5M ($0.29) in 2Q25; R&D expenses $21.5M, up from $16.6M.
- Cash and investments $237M at 6/30/26, up from $145M at 12/31/25; runway into late 2027.
- VMT-α-NET: 76 NET patients treated; Phase 3 planned at cumulative 20 mCi dose; site activation targeted year-end 2026.
- VMT01: 27 patients; 2 partial responses at 3.0 mCi monotherapy; nivolumab combo cohort progressing.
- Appointed Paul Lyne, Ph.D. as Chief Science Officer in July 2026.

## SEC filing metadata
- accession: 0001193125-26-342495
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2026-08-10T20:30:43+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000119312526342495/0001193125-26-342495-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000119312526342495/catx-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-342495
- JSON: https://secwatch.observer/filing/0001193125-26-342495.json
- Plain text: https://secwatch.observer/filing/0001193125-26-342495.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.